Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure

Nisoldipine, a calcium entry blocker, was given to 10 patients with congestive heart failure. During a 2 month follow-up period, 7 of the 10 patients were readmitted with pulmonary edema; daily furosemide doses were increased (128 +/- 87 to 192 +/- 135 mg/day, p less than 0.01), and plasma creatinine increased (1.5 +/- 0.5 to 1.8 +/- 0.6 mg/dl, p less than 0.05) (all values mean +/- SD). Despite this unfavorable clinical course, nisoldipine caused some beneficial chronic (1 month) hemodynamic effects. It decreased systemic vascular resistance (from 1,781 +/- 229 to 1,306 +/- 345 dynes X s X cm-5, p less than 0.01), decreased mean arterial pressure (from 88 +/- 0 to 74 +/- 4 mm Hg, p less than 0.001) and increased stroke volume index (from 27 +/- 6 to 33 +/- 9 ml/min per m2, p less than 0.02). Heart rate, pulmonary capillary wedge pressure and stroke work index did not change. However, nisoldipine's chronic renal and neurohumoral effects were not as favorable. These were assessed during a 5 hour water load (15 ml/kg body weight of 5% dextrose in water) and compared with the effects of a water load before therapy. Nisoldipine did not change creatinine clearance or sodium excretion, but decreased water excretion (from 58 +/- 35 to 46 +/- 40% of water load in 5 hours). Over this 5 hour study, mean plasma vasopressin was also higher with nisoldipine (1.9 +/- 2.3 versus 2.7 +/- 3.2 pg/ml, p less than 0.05), but mean plasma aldosterone was lower (67 +/- 31 to 47 +/- 27 mg/dl, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. Grassi, D. Spaziani, G. Seravalle, G. Bertinieri, R. Dell'Oro, C. Cuspidi, and G. Mancia Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure Hypertension, February 1, 1999; 33(2): 671 - 675. [Abstract] [Full Text] [PDF]

				S. B. Kribbs, W. M. Merritt, M. J. Clair, R. S. Krombach, W. V. Houck, M. G. Dodd, R. Mukherjee, and F. G. Spinale Amlodipine Monotherapy, Angiotensin-Converting Enzyme Inhibition, and Combination Therapy With Pacing-Induced Heart Failure Hypertension, March 1, 1998; 31(3): 755 - 765. [Abstract] [Full Text] [PDF]

				W. Z. Wang, A. Matsumori, T. Yamada, T. Shioi, I. Okada, S. Matsui, Y. Sato, H. Suzuki, K. Shiota, and S. Sasayama Beneficial Effects of Amlodipine in a Murine Model of Congestive Heart Failure Induced by Viral Myocarditis: A Possible Mechanism Through Inhibition of Nitric Oxide Production Circulation, January 7, 1997; 95(1): 245 - 251. [Abstract] [Full Text]

				M. Packer, C. M. O'Connor, J. K. Ghali, M. L. Pressler, P. E. Carson, R. N. Belkin, A. B. Miller, G. W. Neuberg, D. Frid, J. H. Wertheimer, et al. Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure N. Engl. J. Med., October 10, 1996; 335(15): 1107 - 1114. [Abstract] [Full Text] [PDF]

				J. M. Nappi, J. S. Marinac, and P. Bartlome Calcium Channel Blockers Journal of Pharmacy Practice, January 1, 1990; 3(5): 305 - 317. [Abstract] [PDF]